Spero Therapeutics, Inc.
SPRONASDAQHealthcare● Active
$2.81
+$0.07(+2.37%)
Market Cap$162413688
P/E Ratio—
52W High$3.22
52W Low$1.8
Spero Therapeutics, Inc. (SPRO) · Cash Flow
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · SPRO · as of 2026-06-10
Financial statements
Operating CF · CapEx · Free Cash Flow
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | $8.57M | ($68.57M) | $22.81M | ($46.41M) | ($89.76M) |
| Depreciation & Amort. | $0.00M | $0.00M | $0.37M | $1.55M | $1.12M |
| Stock-Based Comp. | $4.33M | $7.79M | $7.93M | $0.00M | $0.00M |
| Change in Working Capital | ($27.16M) | $36.28M | ($70.38M) | $22.09M | $12.86M |
| Net Cash from Operations | ($12.62M) | ($23.44M) | ($32.99M) | ($7.73M) | ($64.35M) |
| Investing Activities | |||||
| Capital Expenditure | $0.00M | $0.00M | $0.00M | $0.00M | $64.35M |
| Purchases of Investments | $0.00M | $0.00M | $0.00M | ($26.97M) | ($43.91M) |
| Sales of Investments | $0.00M | $0.00M | $0.00M | $60.78M | $51.55M |
| Net Cash from Investing | $0.00M | $0.00M | $0.00M | $33.81M | $7.67M |
| Financing Activities | |||||
| Common Stock Repurchased | $0.00M | $0.00M | $0.00M | $0.00M | $0.00M |
| Dividends Paid | $0.00M | $0.00M | $0.00M | $0.00M | $0.00M |
| Debt Issued / Repaid | $0.00M | $0.00M | $0.00M | ($54.48M) | $47.48M |
| Net Cash from Financing | $0.00M | $0.00M | $0.22M | ($29.55M) | $84.05M |
| Free Cash Flow | |||||
| Free Cash Flow | ($12.62M) | ($23.44M) | ($32.99M) | ($7.73M) | $0.00M |
| FCF Margin %(computed) | -21.17% | -48.87% | -31.79% | -15.91% | 0.00% |
Data source: Financial Modeling Prep · Last updated: 2026-06-10 · USD · M
Explore more Spero Therapeutics, Inc. data
About Spero Therapeutics, Inc. (SPRO) Cash Flow Statement
Spero Therapeutics, Inc. generated operating cash flow of ($0.01B) and free cash flow of ($0.01B) for 2025 — a FCF margin of -21.17%. Capital expenditure was $0.00B.
Frequently asked questions
SPRO · 4 questionsSpero Therapeutics, Inc. generated free cash flow of ($0.01B) for 2025, up 46.2% year-over-year.
SPRO free cash flowFCF margincash flow yield
· Source: FMP /stable/cash-flow-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-10